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Abstract
Chronic pancreatitis (CP) is a heterogeneous disease, with 
different causes and often a long delay between onset and 
full classic presentation. Clinical presentation depends on 
the stage of the disease. In earlier stages, recurrent episodes 
of acute pancreatitis are the major signs dominating clinical 
presentation. As the inflammatory process goes on, less 
acute episodes occur, and pain adopts different aspects or 
may even disappear. After 10–15 years from onset, function-
al insufficiency occurs. Then, a classic presentation with pain 
and pancreatic exocrine and endocrine insufficiency ap-
pears. Diagnosis remains challenging in the early stages of 
the disease, as its initial presentation is usually ill-defined 
and overlaps with other digestive disorders. Computed to-
mography and magnetic resonance cholangiopancreatog-
raphy should be the first choice in patients with suspected 
CP. If the results are normal or equivocal but still there is a 
high suspicion of CP, the next option should be endoscopic 
ultrasound. Endoscopic retrograde cholangiopancreatogra-
phy is mainly a therapeutic technique, and for the diagnostic 
purpose should only be used when all other imaging mo-
dalities and pancreatic function tests have been exhausted. 
Indirect tests are used to quantify the degree of insufficiency 
in already-established late CP. Recommendations on CP 
were developed by Clube Português do Pâncreas (CPP), 
based on literature review to answer predefined topics, sub-
sequently discussed and approved by all members of CPP. 
Recommendations are separated in two parts: “chronic pan-
creatitis etiology, natural history, and diagnosis,” and “chron-
ic pancreatitis medical, endoscopic, and surgical treatment.” 
This abstract pertains to part I.
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Recomendações do Clube Português do Pâncreas 
sobre Pancreatite Crónica: Etiologia, História Natural 
e Diagnóstico (Parte I)
Palavras-Chave
Pancreatite crónica · Fisiopatologia · Apresentação 
clínica · História natural · Diagnóstico
Resumo
A pancreatite crónica (PC) é uma doença heterogénea, 
com diferentes etiologias, muitas vezes, com um longo 
período entre o início de sintomatologia e a apresentação 
clínica clássica. A clínica depende do estadio da doença, 
sendo que nos estadios iniciais, predominam episódios 
recorrentes de pancreatite aguda; com a progressão da 
doença, os episódios agudos tornam-se menos frequen-
tes, e a dor adota padrões diferentes, podendo inclusive 
desaparecer; a insuficiência funcional desenvolve-se 10 a 
15 anos após o início, assumindo-se então, a apresenta-
ção clássica com dor, insuficiência pancreática exócrina e 
endócrina. O diagnóstico pode ser desafiador nos esta-
dios iniciais da doença, já que a apresentação inicial é ger-
almente mal definida e se sobrepõe a outros patologias 
gastrointestinais. A TAC e CPRM devem ser os primeiros 
métodos de imagem em doentes com suspeita de PC. Se 
os resultados forem normais ou ambíguos, a próxima op-
ção deve ser a ecoendoscopia. A CPRE é uma técnica prin-
cipalmente terapêutica, sendo que para fins de diagnósti-
co, deve ser reservada para quando todas os outros exa-
mes de imagem/testes de função pancreática forem 
inconclusivos. Testes indiretos de função pancreática de-
vem ser usados para quantificação do grau de insuficiên-
cia pancreática em doentes com PC já estabelecida. As 
recomendações sobre PC foram desenvolvidas pelo Clube 
Português do Pâncreas (CPP), com base numa revisão da 
literatura para responder a questões predefinidas, poste-
riormente discutidos e aprovados por todos os membros 
do CPP. As recomendações encontram-se separadas em 
duas partes: “etiologia da pancreatite crónica, história 
natural e diagnóstico” e “tratamento médico, endoscópi-
co e cirúrgico da pancreatite crónica.” Este resumo corre-
sponde à parte I. © 2019 Sociedade Portuguesa de Gastrenterologia  
Publicado por S. Karger AG, Basel
Introduction
Chronic pancreatitis (CP) is an inflammatory disease 
that causes progressive and irreversible damage to the pa-
renchyma of the organ, leading to progressive scarring of 
the pancreatic tissue with consequent loss of function. 
Recent studies point to an increasing incidence of CP 
over the past decade, which probably reflects an improve-
ment in diagnosis and changes in disease definition [1, 2]. 
The reported annual incidence, roughly similar in all 
countries, ranges from 5 to 14 cases per 100,000 individu-
als [1, 3–5] with a prevalence of approximately 30–50 per 
100,000 individuals, being 5 times more frequent in men 
than in women [6]. 
The pathophysiology of CP is fairly complex and in-
completely understood [4]. Pancreatic stellate cells, re-
sponsible for secretion of excessive amounts of extracel-
lular matrix proteins, play a major role in pancreatic in-
jury [7, 8]. CP is a heterogeneous disease, with different 
causes and often a long delay between the onset and full 
classic presentation. Functional consequences include re-
current or constant abdominal pain, diabetes mellitus 
(DM) (endocrine insufficiency), and maldigestion (exo-
crine insufficiency) with consequent malnutrition. Diag-
nosis remains challenging in the early stages of the dis-
ease, as its initial presentation is usually ill-defined and 
overlaps with other digestive disorders. On the other 
hand, later stages may present with calcification of the 
pancreatic parenchyma, anatomic changes of the pancre-
atic ducts, associated collections, vascular complications, 
and bile duct or duodenal lumen obstruction.
The aims of treatment include lifestyle modifications, 
nutrition, exocrine and endocrine pancreatic insufficien-
cies correction, and pain management. Other therapeutic 
options comprise endoscopic and surgical interventions. 
This paper refers to part I of Clube Português do Pân-
creas (CPP) recommendations for CP management. The 
recommendations were initially based on literature re-
view to answer predefined topics, subsequently discussed 
and approved by all members of CPP.
Etiology and Risk Factors
Both genetic and environmental factors have been as-
sociated with CP [7]. The TIGAR-O classification pro-
poses risk modifiers that may interact with each other to 
produce CP [9] (Table 1). 
The association between alcohol and smoking and CP 
is dose-dependent [1, 7]. Chronic alcohol abuse is re-
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sponsible for 40–70% of CP cases in western countries 
[1]. Although at least 60–80 g of ethanol/day during 5–10 
years is required for CP development [1, 3], less than 10% 
of heavy drinkers develop alcohol-induced pancreatitis 
[7]. Alcohol sensitizes the pancreas to other external fac-
tors, such as smoking and diet, which, along with genetic 
predisposition, interact to increase alcohol toxicity [7].
Cigarette smoking, apart from being an independent 
risk factor, also accelerates CP disease course [7, 10] and 
significantly increases the risk of secondary pancreatic 
cancer and overall mortality [3]. The relative risk of de-
veloping CP is 3-fold higher in heavy smokers (> 1 pack/
day) [4].
Non-alcohol- and non-tobacco-associated CP ac-
counts for 20–50% of cases in western countries [1]. He-
reditary pancreatitis is a rare cause of CP (prevalence of 
0.3/1,000,0000 individuals) [1], and only mutations in the 
PRSS1 gene (which encodes trypsin 1) appear sufficient 
to cause the disease [3]. The inheritance pattern is auto-
somal dominant with an incomplete penetrance (80%). 
All other identified mutations and polymorphisms should 
be considered as cofactors or modifiers that increase the 
severity of disease [3]. Mutations in SPINK1 and CTRC 
(involved in controlling intrapancreatic trypsin 1 activi-
ty) are strongly associated with recurrent acute and CP. 
Mutations in the CFTR genes are also commonly identi-
fied. 
Autoimmune pancreatitis (AIP) represents 2–4% of 
cases of CP and encompasses two different chronic enti-
ties [11]. In type 1 AIP, patients are usually older, with a 
mean age at disease onset of 60–70 years [4, 7]. Involve-
ment of other organs occurs in about 60% of patients (bil-
iary strictures, retroperitoneal fibrosis, pseudotumors, 
and sialoadenitis). Many of the plasma cells and CD4+ T 
cells that infiltrate the pancreas express IgG4 on their sur-
face and elevation in serum levels of IgG4 can be found in 
about 2/3 of patients [4]. Type 2 AIP, less frequent than 
type 1 and typically occurring in younger patients (40–50 
years) [7], is limited to the pancreas and is not associated 
with an infiltration of IgG4+ cells [11].
Idiopathic CP represents 10–30% of CP cases [7] and 
is more common in women [4]. Interpreting idiopathic 
CP literature is difficult, as many patients are probably 
mislabeled, with possible contributions of less severe 
CFTR and SPINK1 gene mutations. Idiopathic CP can 
present in two different forms: an early onset type (ap-
pearing in the late second or third decade of life) and a 
late-onset form (in the sixth or seventh decade) [4]. Trop-
ical pancreatitis, also known as fibrocalculous pancreatic 
diabetes, is a form of idiopathic early-onset pancreatitis 
mainly reported in developing countries [11].
Obstruction of the main pancreatic duct (benign or 
malignant causes) can also lead to CP [4]. Acquired stric-
tures can occur after severe attacks of acute pancreatitis, 
trauma, duodenal wall cysts, sphincter of Oddi dysfunc-
tion [9], or as a consequence of tumor obstruction (ade-
nocarcinoma, islet cell tumor, intraductal papillary muci-
nous neoplasms or ampullary neoplasms) [4]. Pancreas 
divisum, a common normal variant, is rarely considered 
a cause of CP [4]. Many patients with pancreas divisum 
often have coexistent genetic mutations that may contrib-
ute to CP [3].
Recurrent episodes of acute pancreatitis may also lead 
to the development of a chronic inflammatory response, 
culminating in CP. This can also occur even with just one 
severe attack of acute pancreatitis, usually associated with 
significant pancreatic necrosis and the need for surgical 
necrosectomy [4]. 
Table 1. Etiologies of chronic pancreatitis according to the TI-
GAR-O system
Toxic-metabolic Alcohol
Tobacco
Hypercalcemia
Hypertriglyceridemia
Chronic kidney disease
Medications
Idiopathic Tropical chronic pancreatitis
Early-onset
Late-onset
Genetic Autosomal dominant: hereditary pancreatitis
PRSS1 mutations
Autosomal recessive/modifier genes
CFTR mutations
SPINK1 mutations
CTRC mutations
Other
Autoimmune Type 1 (IgG4-related) and type 2
Recurrent and 
severe acute pan-
creatitis
Postnecrotic (after severe necrotizing 
 pancreatitis)
Vascular disease/ischemia
Obstructive Pancreas divisum
Sphincter of Oddi disorders
Malignant pancreatic duct obstruction
Posttraumatic pancreatic duct scars and 
 strictures
CFTR, cystic fibrosis transmembrane conductance regulator; 
CTRC, chymotrypsin C; PRSS1, cationic trypsinogen; SPINK1, 
serine protease inhibitor Kazal type 1.
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Natural History and Prognosis
CP natural history can be divided into an early phase 
(first 5 years of disease, characterized by acute pancreati-
tis episodes, pain, and hospitalizations), a middle phase 
(from 5 to 10 years, characterized by less acute manifesta-
tions, while morphological changes become evident), and 
a late phase (from approximately 10 years onwards, with 
acute manifestations becoming rare and symptoms of en-
docrine and exocrine insufficiency emerging) [12]. The 
progression and duration of each phase is highly variable 
and dependent on the etiologic factors of CP. Further-
more, the sequence of events can occur in all possible 
manners. 
Prognosis of CP is variable and largely depends on the 
presence of ongoing alcohol consumption and associated 
cigarette smoking. Sustained alcohol intake increases 
mortality risk by an additional 60% [4]. The risk of pan-
creatic cancer in patients with chronic alcoholic pancre-
atitis at 10 and 20 years is 1.8 and 4%, respectively. The 
cumulative proportion of patients with pancreatic cancer 
in this population 20 years after CP diagnosis is 4% [1]. 
Concerning hereditary CP, the cumulative proportion of 
patients with pancreatic cancer is 1.5% at 20 years, 8.5% 
at 40 years, and 25% at 60 years after symptom onset [1]. 
The cause of death in patients with CP is usually related 
to other medical conditions associated with smoking, al-
cohol abuse, pancreatic cancer, and postoperative com-
plications rather than CP itself [4]. Ten-year and 20-year 
survival rates in patients with CP are approximately 70 
and 45%, respectively [4].
Diagnosis
Statement
Computed tomography (CT), magnetic resonance 
cholangiopancreatography (MRCP), and endoscopic ret-
rograde cholangiopancreatography (ERCP) all have com-
parable high diagnostic accuracy in the initial diagnosis of 
CP [13]; endoscopic ultrasound (EUS) and ERCP outper-
form the other imaging techniques, while transabdominal 
ultrasound is the least accurate. As diagnostic sensitivity of 
CT and MRCP is not significantly lower than that of ERCP 
and EUS, and specificity is comparable, these noninvasive 
modalities are a likely first choice in patients with suspect-
ed CP. If the results are normal or equivocal but still there 
is a high suspicion of CP, the next choice should be EUS 
mainly due to its high accuracy in general and for early CP 
in particular. Due to its invasiveness and risks, ERCP 
should be the last choice when all other imaging modalities 
and pancreatic function tests have been exhausted. Equiv-
ocal results of imaging modalities should always be inter-
preted according to the clinical presentation and pancre-
atic function tests. Monitoring of symptoms and repetition 
of imaging modalities should also be considered (Fig. 1). 
Functional evaluation should be always considered as even 
mild-to-moderate pancreatic exocrine insufficiency (PEI) 
can lead to deficiencies of several nutrients and clinical im-
plications. The fecal elastase (FE) test is most frequently 
used in this setting, while the 13C mixed triglyceride breath 
test offers an alternative. The secretin-enhanced MRCP 
test may also be used as an indicator of PEI but provides 
only semiquantitative data.
The diagnosis of CP is based on clinical history, imag-
ing modalities, and pancreatic function testing. Due to 
the insufficient correlation of these three diagnostic pil-
lars, they should be used in a complementary way.
Clinical presentation depends on the stage of the dis-
ease. While in earlier stages, recurrent episodes of acute 
pancreatitis predominate, as the inflammatory process 
goes on, less acute episodes occur and pain adopts differ-
ent aspects or may even disappear (burnout theory) [14]. 
After 10–15 years from onset, functional insufficiency oc-
curs (exocrine and endocrine), and pain is very prevalent 
[15]. 
Even though pain is the dominant symptom, around 
20% of the patients may be completely asymptomatic 
[16]. Abdominal pain is mediated by mononuclear cell 
inflammation and infiltration, fibrosis, protein plugs, cal-
cifications, and ductal changes. Later stages are frequent-
ly associated with complications in and around the pan-
creas (biliary obstruction, vascular thrombosis), which, 
by themselves, are also pain promoters.
PEI is clinically evident only when 90% of the function 
is lost, which is classically related to the large functional 
reserve of the pancreas [17, 18]. Clinically, steatorrhea is 
the most prominent symptom of PEI; however, loose and 
greasy voluminous stool appearance is present only in 
overt steatorrhea, as slight to moderate elevation of fecal 
fat content may be completely unnoticed. Lipid malab-
sorption is more evident and precedes for years the overt 
malabsorption of proteins and carbohydrates [19]. Mal-
absorption of fat-soluble vitamins may occur, but clinical 
symptomatic vitamin deficiency is rare [20]. The absorp-
tion of calcium, magnesium, and essential fatty acids is 
also impaired, and significant bone loss may be present 
[17]. Another late-onset complication of PEI is the ap-
pearance of cardiovascular events [21], due to malabsorp-
tion of fatty acids and amino acids, leading to reduced 
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plasma levels of high-density lipoprotein C and A (ath-
erogenesis protectors) [22]. As a result of exocrine insuf-
ficiency, weight loss is expected anytime. Nutritional sta-
tus evaluation is of major importance and helps to assess 
the impact of PEI in patients not only by the time of di-
agnosis but also monitoring disease development and the 
efficacy of treatment.
Overt DM usually occurs late in CP. Around 60–75% 
of CP patients and up to 90% of calcifying CP patients 
have DM, and those with alcohol intake will develop in-
sulin insufficiency earlier [15]. DM may also be the first 
manifestation of painless forms of pancreatitis (20%) 
[23]. As fibrosis increases, islet cell injury with beta-cell 
mass reduction leads to impairment of insulin secretion 
[24]. As type 1 DM, CP-related diabetes (type 3) usually 
requires insulin therapy. However, the major difference 
between them is the simultaneous decrease in alpha cells 
that occurs in type 3 DM, leading to glucagon impair-
ment and, therefore, increased risk of hypoglycemia, 
both spontaneous and treatment related [25, 26]. Type 3 
DM has the same diagnostic criteria as type 1 or 2: fasting 
plasma glucose ≥126 mg/dL (at least 8 h fasting), oral 
glucose tolerance test at 2 h ≥200 mg/dL or HbA1c 
≥6.5%. Treatment with insulin is the standard of care, 
even though metformin may sometimes be used as a first 
approach in patients with a high ratio insulin/C-peptide, 
HbA1c ≤7%, high body mass index, and family history 
of DM. 
Functional Tests
PEI can be defined as an inadequate pancreatic en-
zyme activity due to insufficient enzyme production, in-
sufficient enzyme activation, or early enzyme degrada-
tion. In order to assess pancreatic function, direct and 
indirect methods exist. In cases of CP clinical suspicion, 
a functional evaluation should be performed because 
even mild-to-moderate PEI (“compensated PEI”) can 
disturb the digestive process and lead to deficiencies of 
several nutrients and clinical implications [20]. Direct 
tests estimate the products released in pancreatic secre-
tion (bicarbonate and enzymes), while indirect tests eval-
uate the pancreatic function through the presence or 
quantification of pancreatic enzymes in serum and stool 
or by the presence of labelled carbon dioxide (CO2) in 
exhaled air [20].
Even though the direct test secretin-pancreozymin test 
is considered the gold standard for diagnosis of PEI (sen-
sitivity and specificity >  90%), it has been progressively 
abandoned, as it is an invasive, time consuming, nonstan-
dardized, and expensive method [27]. The endoscopic se-
cretin/pancreatic function test is a variant of the previous 
secretin test, avoiding problems associated with the stan-
dard test, having also a high sensitivity for detecting PEI 
[28].
Compared to direct tests, indirect tests of pancreatic 
exocrine function are less sensitive and specific but cheap-
Endoscopic ultrasound ± elastography, contrast enhancement, t issue acquisit ion
Chronic pancreatitis diagnostic criteria: ≥5 standard endoscopic ultrasound criteria
If results are equivocal, proceed to the next step 
Direct (invasive) pancreatic function testing
Chronic pancreatitis diagnostic criteria: peak (bicarbonate) <80 mEq/L
If results are equivocal, proceed to the next step 
Endoscopic retrograde cholangiopancreatography
Chronic pancreatitis diagnostic criteria: Cambridge grade 3 or 4
If results are equivocal, consider clinical monitoring and repeating previous test
Computed tomography scan and/or magnetic resonance imaging with
cholangiopancreatography ± secretin
Chronic pancreatitis diagnostic criteria: Cambridge grade 3 or 4
If results are equivocal, proceed to the next step 
Clinical history, physical exam, routine lab tests, consider indirect (noninvasive)
pancreatic function testing
Fig. 1. Algorithm approach to diagnosis of 
chronic pancreatitis.
CPP Recommendations for Chronic 
Pancreatitis: Part I
351GE Port J Gastroenterol 2019;26:346–355
DOI: 10.1159/000497388
er and easier to administer [29]. The basis of indirect tests 
is to detect alterations due to loss of pancreatic exocrine 
function. They are best used to quantify the degree of in-
sufficiency in already-established late CP [30] and gener-
ally should be accompanied by cross-sectional CT or 
magnetic resonance imaging to rule out malignancy [31].
Urine tests are rarely used as they have been replaced 
by the FE and direct tests which have better specificity and 
sensitivity [29]. Blood tests to evaluate PEI consist of the 
measurement of serum immunoreactive trypsinogen [29] 
and have been validated for PEI assessment in the context 
of cystic fibrosis [32].
Stool Tests
Although the 3-day fecal fat test is considered the gold 
standard to diagnose steatorrhea (92% of sensibility), it 
has only 42% specificity for PEI, as it does not distinguish 
between pancreatic and nonpancreatic causes of PEI [33].
Elastase is a pancreatic-specific protease, which is not 
degraded by the intestine, and has a 5–6 times higher con-
centration in stool compared to pancreatic secretion [34]. 
A low FE concentration of <  200 μg/g suggests PEI, where-
as < 100 μg/g suggests severe PEI [30]. Classic false-posi-
tive FE measurements (low levels) occur in small bowel 
bacterial overgrowth and watery stool. Classic false-neg-
ative serum trypsin measurements (normal/high levels) 
occur when performed in the setting of acute pancreatic 
inflammation [31]. Its sensitivity and specificity range, 
respectively, from 0 to 63% and 80 to 95% in mild-to-
moderate PEI and from 77 to 100% and 76 to 100% in 
moderate-to-severe PEI [35]. Fecal chymotrypsin is no 
longer employed because the FE test has more sensitivity 
and specificity [29].
Microscopic examination of stools for fat droplets 
works just as a screening test that can be performed before 
additional tests, in order to detect fat globules. 
Breath Tests
Radiolabeled carbon breath tests samples are taken be-
fore and after a test meal containing 13C-labeled sub-
strate. The most widely used test is the 13C-labeled mixed 
triglyceride breath test [25]. It involves the ingestion of 
250 mg of 2-octanoyl (1–13C)-1.3 distearoyl glycerol 
(Euriso-top, Saint-Aubin, France) with 16 g of fat. This 
substrate is digested by lipase, releasing 13C-labeled octa-
noic acid, which is then absorbed and metabolized to 
form 13CO2, ultimately released in expired breath. Breath 
samples are collected at 15 min intervals for 6 h [36]. It 
might be an accurate and alternative method to the quan-
titative fecal fat test to assess the effect of enzyme therapy 
on fat digestion and the correction of fat malabsorption 
during therapy [29]. Its limitations are its poor sensibility 
in the absence of steatorrhea and inability to differentiate 
between pancreatic and nonpancreatic causes of fat mal-
absorption [29].
Imaging Modalities
Imaging modalities are indispensable for the diagnosis 
of CP and its complications. Diagnosis of CP by imaging 
modalities relies on changes in morphology of the pan-
creas, easily detected in advanced CP, but hardly recog-
nized in early disease [31, 37, 38].
Computed Tomography
The classical CT findings in CP are dilatation of the 
pancreatic duct, pancreatic calcifications, and parenchy-
mal atrophy. The main pancreatic duct is classically bead-
ed and irregular; however, the main duct may also be reg-
ularly contoured. CT is considered the most appropriate 
method for identifying pancreatic calcifications. Never-
theless, very small calcifications may be obscured by pan-
creatic parenchymal contrast enhancement, and thus 
pancreatic CT should include a non-contrast-enhanced 
phase. Additionally, while pancreatic atrophy is visual-
ized in a large proportion of patients with CP, this is not 
a specific finding and can also be seen with normal aging.
CT is especially helpful in identifying complications of 
CP, including pseudocysts, portosplenic venous throm-
bosis, collaterals and arterial pseudoaneurysms, and pan-
creatico-pleural fistulas [31, 37, 38]. CT may also be use-
ful in the differential diagnosis between mass-forming 
pancreatitis and pancreatic cancer [20]. Features that fa-
vor CP are intraductal or parenchymal calcifications, lack 
of obstructing mass, irregular dilatation of the pancreatic 
duct, and relatively limited atrophy of the gland. The 
presence of a “duct-penetrating” sign (dilated duct or 
branches which penetrate an apparent mass) favors CP. 
Features favoring cancer include pancreatic duct dilata-
tion with associated mass at the site of obstruction, atro-
phy of the pancreas, vascular invasion, and metastases. 
CT is considered by many as the best initial imaging test 
in the workup for CP since it is widely accessible, allows 
for comprehensive detailed evaluation of the pancreas, 
and it is especially useful in detecting changes seen in ad-
vanced disease and complications of CP. Moreover, it can 
quickly assess extrapancreatic pathology that may explain 
various presentations mimicking CP. It has, however, two 
important limitations, namely the evaluation of pancre-
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atic ductal anatomy and the initial parenchymal changes 
for CP early diagnosis; it also poses the risk of radiation.
Magnetic Resonance Imaging with 
Cholangiopancreatography
MRCP is highly sensitive and specific in diagnosing 
CP by evaluating both parenchymal and ductal changes, 
especially in patients with more advanced CP [31, 37, 38]. 
Parenchymal changes that are visualized include pancre-
atic atrophy, depressed T1 signal, irregular contour of 
head or body, heterogeneous parenchyma, and delayed 
enhancement of the pancreas after gadolinium adminis-
tration. Ductal changes include intraductal filling defects 
often indicative of calculi, main pancreatic duct dilation, 
side branch dilation, and irregular duct contour. While 
there are no standardized criteria for diagnosing CP with 
the use of MRCP, the Cambridge classification for ERCP 
may be adapted (Table 2) [31, 37, 38]. This classification 
may also be helpful in interpreting and grading the find-
ings of other imaging modalities, namely transabdominal 
ultrasound and CT.
Secretin-enhanced MRCP has been shown to amelio-
rate sensitivity in early CP [39, 40]. Besides enhancing 
visualization of the main pancreatic duct and abnormal 
side branches compared to conventional MRCP (increas-
ing the overall sensitivity for the detection of ductal 
changes of CP) [41], it also estimates exocrine function 
(through evaluation of pancreatic duct compliance and 
pancreatic duct flow rate) which correlates well with the 
severity of pancreatitis [40].
MRCP has a high sensitivity and specificity in the dif-
ferential diagnosis of pancreatic masses [42]. This is large-
ly based on the same findings described for CT, especially 
the “duct-penetrating” sign. However, this does not apply 
when a carcinoma develops in the presence of CP. In this 
case, like with all imaging modalities, the sensitivity and 
specificity is significantly reduced and inferior to that doc-
umented for EUS-guided tissue acquisition. 
Endoscopic Ultrasound
Due to its superior spatial resolution, EUS is consid-
ered the most sensitive imaging technique for the diagno-
Table 2. Cambridge classification for transabdominal ultrasound (US), computed tomography (CT), magnetic resonance imaging with 
cholangiopancreatography (MRCP) and endoscopic retrograde cholangiopancreatography (ERCP) findings in chronic pancreatitis
Grade US CT/MRCP ERCP
0 Normal organ, duct <2 mm, regular 
contour
None No pathological alterations 
on good visualization of 
pancreatic duct system
1 Echo-dense gland contour, gland 
 enlarged (up to 1.5-fold),
duct <3 mm, lobular honeycomb 
 appearance
Not possible to demarcate duct system on CT/
MRCP using current methods
<3 abnormal side branches, 
main duct normal
2 Contour irregularities, irregular hyper-
echoic main pancreatic duct >3 mm, 
lobular texture with echo-dense septa-
tions
≥2 of the following changes: pancreatic duct 
between 2 and 4 mm in the pancreatic body; 
mild pancreatic enlargement; heterogeneous 
parenchymal structure; small cystic changes 
(<10 mm); duct irregularities; pathological side 
branches >3
>3 abnormal side branches, 
main duct normal
3 As in 2, plus cysts, focal calcifications All changes named under 2 plus pathological 
main duct (>4 mm)
≥3 abnormal side branches 
plus abnormal main pancre-
atic duct
4 As in 3, plus duct stones, duct obstruc-
tion, tumorous enlargement of the 
gland >2-fold, splenic vein thrombosis
One of the changes named under 2 or 3 plus  
≥1 of the following: cystic structures >10 mm; 
parenchymal calcifications; intraductal filling 
defects (calcifications); duct obstruction 
 (strictures); major duct irregularities
As in 3, plus cysts, duct 
calculi, duct obstruction 
(stricture), involvement of 
adjacent organs
Cambridge grades 3 and 4 are considered diagnostic of chronic pancreatitis.
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sis of CP, mainly during the early stages of the disease. 
EUS evaluates both parenchymal and ductal changes of 
CP. A total of 9 EUS criteria (4 parenchymal and 5 ductal) 
have been proposed by the International Working Group 
in the diagnosis of CP (Table 3) [43]. Currently, there is 
no optimal cut-off for establishing a EUS diagnosis of CP, 
even though a minimum of 5 criteria are often required 
[31, 38, 39, 44]. The presence of 5 or more findings pro-
vides a definitive diagnosis of CP, whereas 2 or less find-
ings effectively rule out this disease. Patients with 3–4 cri-
teria have an indeterminate diagnosis and should be thor-
oughly worked up further with pancreatic function 
testing. The 9 criteria have been linked to distinct histo-
logical changes noted from specimens collected after EUS 
evaluation [45]. Given the lack of standardization across 
EUS interpretation in the context of CP, the Rosemont 
criteria were developed [46]; however, this classification 
is more complex and does not improve the diagnostic val-
ue of the standard criteria.
Like other imaging modalities, EUS is also able to detect 
multiple complications of CP, in particular pancreatic can-
cer. Although there is no clear consensus on whether and 
how to conduct pancreatic cancer screening in CP, many 
centers recommend the use of EUS, based on its ability to 
identify small pancreatic masses, even though this ability 
is reduced in the presence of CP. EUS-guided tissue acqui-
sition is an essential tool in the differential diagnosis be-
tween mass-forming CP and pancreatic cancer [39]. In 
fact, EUS-guided tissue acquisition is considered the most 
reliable procedure for detecting pancreatic malignancy in 
patients with or without CP, although in CP the sensitivity 
decreases from 80–95 to 50–75% [39]. There is also a prob-
ability of false negatives (5–10%), and thus in patients with 
suspected operable pancreatic cancer in imaging modali-
ties, surgery is recommended even without prior cytologi-
cal confirmation. New EUS imaging techniques, such as 
elastography (E-EUS) and contrast-enhanced harmonic 
EUS (CEH-EUS) have also been proposed to increase the 
accuracy of EUS in the differential diagnosis between 
mass-forming CP and pancreatic cancer, not only by al-
lowing better morphological characterization of the mass, 
but also by directing EUS-guided tissue acquisition. Al-
though two recent meta-analyses [44, 45] have demon-
strated that CEH-EUS and E-EUS are reliable techniques 
for the characterization of solid pancreatic masses, most 
studies were unicentric and included low numbers of pa-
tients with CP [47, 48]. Several computer-aided diagnosis 
methods for E-EUS and CEH-EUS may reduce various bi-
ases and increase the accuracy of EUS in this setting, but 
their role in the characterization of solid pancreatic lesions 
in patients with CP is still unclear.
Endoscopic Retrograde Cholangiopancreatography
Nowadays, the use of ERCP in the management of CP 
is typically limited to therapeutic interventions. Histori-
cally, specific findings described in CP by a retrograde 
pancreatogram obtained during ERCP include the main 
pancreatic duct caliber and contour, clear definitions of 
its side branches, intraductal filling defects, strictures, 
and cavity formation. Although ERCP is sensitive for de-
tection of changes in the pancreatic duct, there are sev-
eral drawbacks when it is used for the diagnosis of CP. 
Like EUS, it is operator-dependent and prone to interob-
server variability. It does not provide assessment of the 
classic parenchymal CP changes. Moreover, it is the most 
invasive diagnostic modality and carries postprocedural 
risks, most notably, post-ERCP pancreatitis. Finally, oth-
er potential confounders to interpretation of pancreato-
grams include age-related ductal changes and postacute 
pancreatitis ductal changes which are indistinguishable 
from ductal changes related to CP. For these reasons, 
ERCP should be used for diagnosing CP only when all 
other imaging modalities have been exhausted.
Table 3. Endoscopic ultrasound criteria for chronic pancreatitis and histological correlates (International Work-
ing Group in the diagnosis of CP)
Parenchymal criteria Histologic correlate Ductal criteria Histologic correlate
Hyperechoic foci
Hyperechoic strands
Lobular contour
Cysts
Focal fibrosis
Bridging fibrosis
Interlobular fibrosis
Cyst/pseudocyst
Calcified stones
Main duct dilation (mm)
Duct irregularity
Hyperechoic margins
Visible side branches
Stones
>3 head, >2 body, >1 tail
Focal dilation/narrowing
Periductal fibrosis
Side branch dilation
Calcified stones
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Conclusion
CP is a heterogeneous disease, with different causes 
and often a long delay between onset and full classic pre-
sentation. Clinical presentation depends on the stage of 
the disease. In earlier stages, recurrent episodes of acute 
pancreatitis are the major signs dominating clinical pre-
sentation. As the inflammatory process goes on, less acute 
episodes occur and pain adopts different aspects or may 
even disappear. After 10–15 years from onset, functional 
insufficiency occurs. Then, a classic presentation with 
pain and pancreatic exocrine and endocrine insufficiency 
appears. Diagnosis remains challenging in the early stag-
es of the disease, as its initial presentation is usually ill-
defined and overlaps with other digestive disorders. CT 
and MRCP should be the first choice in patients with sus-
pected CP. If the results are normal or equivocal but still 
there is a high suspicion of CP, the next choice should be 
EUS, with or without tissue acquisition. ERCP should be 
the last choice when all other imaging modalities and 
pancreatic function tests have been exhausted. Indirect 
tests may have a role in CP differential diagnosis, but their 
major indication is to quantify the degree of insufficiency 
in already-established late CP. 
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